New drug duo aims to shrink throat tumors before surgery
NCT ID NCT07538206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs (vibecortamab and putilimab) before surgery can help shrink tumors in people with locally advanced laryngeal cancer. About 10 adults aged 18-80 with resectable cancer will receive the combination, then have surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (complete response).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an immunotherapy combo shrink throat tumors before surgery?
- New study: can early palliative care help head and neck cancer patients suffer less?
- New lozenge aims to ease radiation mouth sores for hours
- Proton therapy offers new hope for head and neck cancer patients facing second radiation
- New combo injection targets Hard-to-Treat head and neck tumors